Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.61 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 10/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.53 |
| ▸ | LMNA | P02545 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | HTT | P42858 | 5/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499941 | 0.91 | P2RY1 (0.70) | EPHX1EPHX2S1PR2P2RY1MEN1 | |
| SCHEMBL11007336 | 0.88 | KMT2A (0.70) | EPHX1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL6567241 | 0.83 | EPHX1 (0.59) | EPHX1EPHX2S1PR2P2RY1MEN1 | |
| SCHEMBL2097416 | 0.83 | EPHX1 (0.43) | EPHX1EPHX2S1PR2P2RY1MEN1 | |
| SCHEMBL2097418 | 0.83 | THRA (0.44) | EPHX1EPHX2S1PR2P2RY1MEN1 | |
| SCHEMBL20535682 | 0.81 | LMNA (0.56) | MEN1KMT2ALMNAHTTMAPT | |
| SCHEMBL11005058 | 0.78 | KDR (0.85) | EPHX1EPHX2CA2CA9KDR | |
| SCHEMBL15786287 | 0.77 | MEN1 (0.76) | EPHX1EPHX2S1PR2P2RY1MEN1 | |
| SCHEMBL11001550 | 0.77 | MEN1 (0.74) | EPHX1EPHX2P2RY1MEN1KMT2A | |
| SCHEMBL9349095 | 0.76 | KMT2A (0.48) | EPHX1EPHX2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0015110-A2 | Anticoccidial composition, carbanilides and method of preparing them | ELI LILLY AND COMPANY (US) | 1980-09-03 | — | — | EP | claimed |
| US-11583509-B2 | Compound for treating cancer and diabetes | CITY OF HOPE (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220023240-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | CITY OF HOPE | 2022-01-27 | — | — | US | disclosed |
| US-9808434-B2 | Compound for treating cancer and diabetes | CITY OF HOPE (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160354327-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | CITY OF HOPE | 2016-12-08 | — | — | US | disclosed |
| US-20140162996-A1 | NOVEL MODULATORS OF DEVELOPMENT OF ADIPOCYTE AND CANCER CELLS | CITY OF HOPE (US) | 2014-06-12 | — | — | US | disclosed |
| EP-0015110-B1 | ANTICOCCIDIAL COMPOSITION, CARBANILIDES AND METHOD OF PREPARING THEM | ELI LILLY AND COMPANY (US) | 1985-08-21 | — | — | EP | disclosed |
| US-4526997-A | Amino, nitro, fluoro substituted carbanilides | DOHERTY GEORGE O P O | 1985-07-02 | — | — | US | disclosed |
| US-4468380-A | Anticoccidial combinations comprising polyether antibiotics and carbanilides | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | disclosed |
| EP-0015110-A2 | Anticoccidial composition, carbanilides and method of preparing them | ELI LILLY AND COMPANY (US) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023240-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | TP53, VHL, SLC2A4 | EPHX1 3055/4885EPHX2 3211/4885S1PR2 4184/4885 |
| US-11583509-B2 | Compound for treating cancer and diabetes | TP53, VHL, SLC2A4 | EPHX1 3055/4885EPHX2 3211/4885S1PR2 4184/4885 |
| US-20160354327-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | TP53, VHL, SLC2A4 | EPHX1 3055/4885EPHX2 3211/4885S1PR2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.